Shares of Platinum Group Metals Ltd. climbed to a new 52-week high price fueled by high demand and increases in platinum group metals prices. The firm claims its primary objective is now the advancement of the palladium dominant Waterberg Project in South Africa.
Shares of NantKwest Inc. spiked as much as 85% higher, setting a new 52-week high price, after the company reported a series of positive results at the 38th JP Morgan Healthcare Conference in San Francisco. The firm reported that complete responses were noted in as many as six different multiple tumor types when "natural killer" cells and T cells are activated simultaneously.
Pope Resources LP shares set a new 52-week intraday high price after the timber resources firm announced that it agreed to be acquired by Rayonier for $554 million, or $126.91 per unit. The transaction is expected to close in mid-year 2020 subject to approval of Pope's unitholders and customary regulatory approvals.
Rare disease biopharmaceutical company Ultragenyx Pharmaceutical's shares traded 30% higher after the firm reported positive topline results from Cohorts 2 and 3 in its Phase 1/2 study of DTX301 gene therapy in Ornithine Transcarbamylase Deficiency.
Shares of Applied Genetic Technologies skyrocketed to a new 52-week high price after the company reported positive six-month data from its ongoing Phase 1/2 clinical study for treatment in X-Linked Retinitis Pigmentosa. The firm stated that the trial data suggests durable and meaningful improvements in central visual sensitivity and advised that it plans to initiate a pivotal trial by year-end 2020.
Applied Therapeutics' shares traded 25% higher after the company reported positive topline results from its Pivotal Phase 2 ACTION Study of AT-007 for use in the treatment of galactosemia. The firm expects to file for regulatory approval of AT-007 in H2/20.